Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
$21.52
-8.9%
$25.34
$21.37
$31.16
$1.38B1.642.68 million shs4.90 million shs
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
$48.70
-4.1%
$57.48
$36.85
$68.43
$5.34B1.899.21 million shs11.95 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$22.21
+0.1%
$26.65
$20.84
$35.25
$2.22B1.911.28 million shs2.37 million shs
Alphabet Inc. stock logo
GOOGL
Alphabet
$154.33
-4.9%
$179.66
$147.22
$207.05
$1.88T1.0227.28 million shs48.61 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$820.30
-0.2%
$844.31
$711.40
$972.53
$777.78B0.343.31 million shs2.12 million shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$5.22
-1.1%
$6.94
$4.31
$13.24
$463.52M1.771.45 million shs585,375 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$492.69
-2.0%
$476.45
$377.85
$519.88
$126.52B0.411.28 million shs1.28 million shs
The 10 Best Stocks to Own: Spring 2025 Cover

Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
0.00%-7.57%-12.52%-11.93%-25.19%
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
0.00%-5.44%-12.47%-15.47%-2.76%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%-4.68%-15.68%-12.11%-32.78%
Alphabet Inc. stock logo
GOOGL
Alphabet
0.00%-5.89%-9.39%-19.30%+2.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-2.28%-10.88%+6.00%+5.44%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
0.00%-5.95%-17.54%-5.78%-60.69%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%-2.09%+2.69%+23.37%+17.87%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/AN/AN/AN/AN/AN/A
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.2127 of 5 stars
4.51.00.00.03.02.50.6
Alphabet Inc. stock logo
GOOGL
Alphabet
4.5921 of 5 stars
4.43.01.70.03.42.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8006 of 5 stars
2.45.03.34.03.42.51.9
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
1.8107 of 5 stars
3.50.00.00.01.92.50.6
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3.837 of 5 stars
2.33.00.03.33.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
2.73
Moderate Buy$21.52N/A
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
2.61
Moderate Buy$48.70N/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$49.45122.67% Upside
Alphabet Inc. stock logo
GOOGL
Alphabet
2.86
Moderate Buy$210.5936.45% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7223.09% Upside
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
3.00
Buy$25.50388.51% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.65
Moderate Buy$506.702.84% Upside

Current Analyst Ratings Breakdown

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$42.00 ➝ $42.00
3/25/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/19/2025
Alphabet Inc. stock logo
GOOGL
Alphabet
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$220.00 ➝ $220.00
3/19/2025
Alphabet Inc. stock logo
GOOGL
Alphabet
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$200.00 ➝ $200.00
3/19/2025
Alphabet Inc. stock logo
GOOGL
Alphabet
Rosenblatt Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$205.00 ➝ $205.00
3/18/2025
Alphabet Inc. stock logo
GOOGL
Alphabet
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$220.00 ➝ $202.00
3/12/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$34.00
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$57.00
(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/AN/AN/AN/A
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
N/AN/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M34.89N/AN/A$12.04 per share1.84
Alphabet Inc. stock logo
GOOGL
Alphabet
$350.02B5.37$7.92 per share19.49$26.67 per share5.79
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.27$13.37 per share61.34$15.05 per share54.50
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$32.33M14.34N/AN/A$7.31 per share0.71
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.02B11.48N/AN/A$63.90 per share7.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/A0.00N/AN/AN/AN/AN/A
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
N/AN/A41.12N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)
Alphabet Inc. stock logo
GOOGL
Alphabet
$100.12B$8.0519.1715.091.3428.60%32.49%23.52%4/24/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.0526.361.4023.51%85.24%16.19%5/1/2025 (Estimated)
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$200.07M-$2.35N/AN/AN/A-807.65%-35.23%-27.65%5/14/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$2.20N/A28.142.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Alphabet Inc. stock logo
GOOGL
Alphabet
$2.02N/AN/AN/A$89.30 billionN/A
2/27/2025Q4 2024
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$0.72-$0.58+$0.14-$0.58$3.94 million$13.08 million
2/25/2025Q4 2024
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million
2/10/2025Q4 2024
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.99$3.54-$0.45$3.50$2.78 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/4/2025Q4 2024
Alphabet Inc. stock logo
GOOGL
Alphabet
$2.12$2.15+$0.03$2.15$96.67 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/AN/AN/A
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
N/A0.00%N/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.904.05%N/AN/A N/A
Alphabet Inc. stock logo
GOOGL
Alphabet
$0.800.52%N/A9.94%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/4/2025
Alphabet Inc. stock logo
GOOGL
Alphabet
quarterly$0.200.4%3/10/20253/10/20253/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/A
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
N/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
5.69
5.69
Alphabet Inc. stock logo
GOOGL
Alphabet
0.03
1.84
1.84
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/A
13.05
13.05
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.69
2.35
CompanyEmployeesShares OutstandingFree FloatOptionable
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/A47.40 millionN/ANot Optionable
ARK Innovation ETF stock logo
ARKK
ARK Innovation ETF
N/A109.70 millionN/ANot Optionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
51099.79 million79.33 millionOptionable
Alphabet Inc. stock logo
GOOGL
Alphabet
190,20012.19 billion10.78 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
11088.80 million68.32 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,100256.79 million256.28 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ARK Genomic Revolution ETF stock logo

ARK Genomic Revolution ETF BATS:ARKG

$21.52 -2.09 (-8.87%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$21.51 -0.01 (-0.03%)
As of 03/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.

ARK Innovation ETF stock logo

ARK Innovation ETF NYSEARCA:ARKK

$48.70 -2.08 (-4.10%)
Closing price 03/28/2025 04:10 PM Eastern
Extended Trading
$48.56 -0.14 (-0.28%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The ARK Innovation ETF (ARKK) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that seeks long-term capital growth from companies globally involved with, or that benefit from, disruptive innovation. ARKK was launched on Oct 31, 2014 and is managed by ARK.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$22.21 +0.02 (+0.09%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$22.20 -0.01 (-0.05%)
As of 03/28/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Alphabet stock logo

Alphabet NASDAQ:GOOGL

$154.33 -7.91 (-4.88%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$154.26 -0.08 (-0.05%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$820.30 -1.37 (-0.17%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$815.45 -4.85 (-0.59%)
As of 03/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Verve Therapeutics stock logo

Verve Therapeutics NASDAQ:VERV

$5.22 -0.06 (-1.14%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$5.22 0.00 (-0.10%)
As of 03/28/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$492.69 -9.86 (-1.96%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$488.15 -4.54 (-0.92%)
As of 03/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.